+ Watch MDGN
on My Watchlist
Medgenics is making slow progress with their rather dubious Biopump platform. Enrollment has begun in the phase I/II trial of Infradure for hepatitis C in Israel, but interim data doesn't seem to have appeared in late 2013 as promised. And really, how many patients are going to need an interferon pump for hep C after all-oral regimens become the standard of care in the developed world within a year or two? Medgenics has been "on target" to initiate a US phase II trial of Epodure for months, but the trial never seems to actually begin. Medgenics seems much more interested in PR'ing smallish open market purchases of stock by insiders than actually progressing their pipeline. This thinly traded and volatile stock is great fun for traders but hardly investment grade material. Short-term movements are unpredictable but eventually this stock will be revisiting the 4's.
The CEO has paid as much as $10.74 for this on the open arket, and another director went as high as $13.03.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions